Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections
- PMID: 39231504
- PMCID: PMC11458495
- DOI: 10.3947/ic.2024.0038
Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections
Abstract
This guideline aims to promote the prudent use of antibacterial agents for managing carbapenem-resistant Enterobacterales (CRE) infections in clinical practice in Korea. The general section encompasses recommendations for the management of common CRE infections and diagnostics, whereas each specific section is structured with key questions that are focused on antibacterial agents and disease-specific approaches. This guideline covers both currently available and upcoming antibacterial agents in Korea.
Keywords: Antibacterial agents; Carbapenem-resistant Enterobacterales; Practice guideline.
© 2024 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, The Korean Society for AIDS, and Korean Society of Pediatric Infectious Diseases.
Conflict of interest statement
BK is associate editor of Infect Chemother; JYC and JYS editorial board of Infect Chemother; however, they did not involve in the peer reviewer selection, evaluation, and decision process of this article. Otherwise, no potential conflicts of interest relevant to this article was reported.
Similar articles
-
Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria.Infect Dis Ther. 2021 Mar;10(1):75-92. doi: 10.1007/s40121-020-00395-2. Epub 2021 Jan 25. Infect Dis Ther. 2021. PMID: 33492641 Free PMC article. Review.
-
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clin Infect Dis. 2021 Apr 8;72(7):e169-e183. doi: 10.1093/cid/ciaa1478. Clin Infect Dis. 2021. PMID: 33106864
-
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. doi: 10.1093/cid/ciab295. Clin Infect Dis. 2021. PMID: 33830222
-
Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant Enterobacterales Bloodstream Infections.mSystems. 2022 Oct 26;7(5):e0047622. doi: 10.1128/msystems.00476-22. Epub 2022 Aug 29. mSystems. 2022. PMID: 36036505 Free PMC article.
-
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013. Clin Infect Dis. 2022. PMID: 34864936 Review.
Cited by
-
Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.Int Microbiol. 2025 Jun 20. doi: 10.1007/s10123-025-00686-z. Online ahead of print. Int Microbiol. 2025. PMID: 40537692
-
"Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.J Antibiot (Tokyo). 2025 Jul;78(8):457-471. doi: 10.1038/s41429-025-00833-8. Epub 2025 Jun 3. J Antibiot (Tokyo). 2025. PMID: 40461635 Review.
References
-
- Centers for Disease Control and Prevention (CDC) Facility guidance for control of carbapenem-resistant Enterobacteiaceae (CRE): November 2015 update-CRE toolkit. [Accessed 30 March 2024]. Available at: https://stacks.cdc.gov/view/cdc/79104.
-
- World Health Organization (WHO) Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. [Accessed 30 March 2024]. Available at: https://www.who.int/publications/i/item/9789241550178. - PubMed
-
- Korea Disease Control and Prevention Agency (KDCA) National antibiotic-resistant bacteria surveillance annual Report. 2021. [Accessed 30 March 2024]. Available at: https://nih.go.kr/nohas/common/board/readBoardView.do.
-
- Im J, Shim J, Lee H, Hyeon J, Lee S, Park S. Characteristics of Carbapenem-resistant Enterobacteriaceae (CRE) in the Republic of Korea, 2022. Public Health Wkly Rep. 2024;17:115–127.
-
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) Clin Infect Dis. 2021;72:e169–e183. - PubMed